Concomitant potent and moderate CYP3A inducers (without a potent CYP3A inhibitor): 600mg twice daily. Children: <2yrs or <2kg: not recommended.

Concomitant moderate CYP3A4 inhibitors: Avoid another dose of Nurtec ODT within 48 hours. Concomitant strong or moderate CYP3A inducers: Avoid use with Nurtec ODT; may lead to loss of efficacy.

Dosage modifications are recommended for patients with hepatic impairment and those on concomitant moderate CYP3A inhibitors. The use of Journavx for moderate to severe pain has not been studied ...

Three deaths were reported in patients treated with concurrent CYP3A inhibitor and erythromycin use over the course of 194 person-years of follow-up, which amounted to a rate of 1.2 deaths per ...

PF-562271, a potent FAK inhibitor, is under development as an anticancer agent. Preclinical studies demonstrated that PF-562271 is an inhibitor of its primary metabolizing enzyme, CYP3A. PF-562271 PK ...

In a multivariate analysis, moderate/strong CYP3A inhibitor use was associated with a higher risk of any event (HR 1.79, p<0.02), independent of the use or dose of either multi-agent chemotherapy or D ...

GLS4 is a sensitive substrate of CYP3A. CYP3A inhibitors or inducers cause considerable change of GLS4 plasma concentrations in dogs, which should be considered in clinical practice.